中药复方对肝癌小鼠移植瘤体液免疫的影响

为研究中药复方解毒消癥饮和扶正抑瘤方对肝癌小鼠移植瘤体液免疫中免疫球蛋白IgG、IgM及补体C3、C4的影响,将40只雌性C57BL/6j小鼠分为移植瘤不给药组(A)、移植瘤给予复方中药组(B)、无移植瘤给予扶正抑瘤方纽(C)及空白对照组(D),分段给药20 d后测定免疫球蛋白IgG、IgM及补体C3、C4的含量.结果表明A组、B组、C组IgG的含量均显著高于D组(P＜0.01),其中B组IgG含量最高;B组IgM的含量显著高于A组、C组、D组(P＜0.01);移植瘤引起了补体C3、C4水平的下降,但中药复方并没有对补体C3、C4的水平产生影响.中药复方解毒消癥饮和扶正抑瘤方可能是通过调节IgG和IgM的水平起作用.     

黄葵胶囊治疗IgA肾病湿热证蛋白尿的临床观察

目的:观察黄葵胶囊(黄蜀葵花)治疗IgA肾病湿热证的临床疗效。方法:将64例IgA肾病湿热证患者随机分为治疗组和对照组,治疗组32例给予黄葵胶囊4粒,3次/日治疗,对照组采用常规西药福辛普利(蒙诺)10mg,1次/日治疗,疗程12周,观察两组治疗前后中医湿热证证候积分、24h尿蛋白定量、血肌酐、尿素氮的变化及肝功能、电解质、不良事件等安全性指标。结果:两组病人临床资料无统计学差异。治疗12周后对照组和治疗组的24h尿蛋白分别较治疗前降低(0.49±0.78)g/24h和(0.4±0.76)g/24h(P<0.05),两组差异无显著性(P>0.05);对照组和治疗组中医湿热证证候积分分别下降(0.88±1.43)和(1.94±1.63)(P<0.05),两组差异有显著性(P<0.05)。治疗组西医总有效率为53.1%,对照组为65.6%(P>0.05);治疗组中医总有效率84.4%,对照组为50.0%,两组比较差异有显著性(P<0.01)。与治疗前相比,两组的血肌酐、尿素氮均无明显变化(P>0.05)。治疗12周中两组不良事件发生率差异无显著性,且均未发生严重不良事件。结论:黄葵胶囊可以减少IgA肾病湿热证患者...     

5-FU联合胸腺肽对H22细胞皮下移植瘤小鼠免疫功能的影响

目的:探讨5-FU联合胸腺肽的抗肿瘤及免疫调节功效。方法:32只ICR小鼠建立H22小鼠肝癌细胞的皮下移植瘤模型,分为对照组(生理盐水),5-FU组(10mg/kg),5-FU+胸腺肽组(10mg/kg+0.2mg/kg),胸腺肽组(0.2mg/kg),连续给药5天后测量肿瘤重量和体积,检测外周血WBC及淋巴细胞(LY)数量及外周血中CD3+、CD4+、CD8+、NK细胞的百分含量、血清中白介素2(IL-2)和肿瘤坏死因子(TNF-α)的浓度。结果:5-FU联合胸腺肽显著抑制了小鼠皮下移植瘤的生长(P<0.01),胸腺肽上调了5-FU降低的WBC及LY细胞数量(P<0.05),增加外周血中CD3+、CD4+及NK细胞的水平(P<0.05);与对照组比,显著升高了血清中IL-2和TNF-α的浓度(P<0.01)。结论:5-FU联合胸腺肽可增强机体的细胞免疫功能,上调血清中细胞因子的表达水平,具有显著的抗肿瘤功效。而不良反应较小。     

胃肠癌虚实辨证与Th1/Th2细胞因子关系的研究

目的 研究胃肠癌虚实证型与Th1/Th2细胞因子平衡的关系,筛选胃肠癌虚实证型辨证客观化指标.方法选择胃肠癌100例,其中实证组58例,虚证组42例.另选择40例健康人作为对照组.采用酶联免疫方法( ELISA)检测各组外周血白细胞介素(IL)-2、4、-6、-10和干扰素(IFN)-y水平.结果胃肠癌虚实证组均表现出...     

国际健康管理主流研究领域回顾及趋势分析

目的 揭示国际健康管理主流研究领域及其研究趋势,为国内学者及相关机构进行健康管理战略研究领域选择与健康管理学学科建设提供决策依据.方法 采用高频引文同被引聚类分析与高频主题词共词聚类分析相结合的方法,依据各类中的内容分析当前研究的热点,并通过引文战略坐标和主题战略坐标揭示研究历史与趋势.结果 2002年之前和之后的研究热点均有8个子领域,其中既有交叉领域,也有独立领域.结论 健康管理具有多学科特征,目前尚未形成非常成熟、稳定的研究领域;健康管理涉及卫生保健服务全过程的管理;精神健康管理、慢性病健康管理及其初级卫生保健服务是持续性研究热点.健康素养是健康管理中一个值得关注和重视的领域.健康管理应与健康保险实现互动,使其成为医疗保障体系的一部分.

Abstract：

Objectives To identify the mainstream studies and their development trends in health management research, and enable domestic scholars and institutions in their decision making to select strategic research fields and their discipline development on health management. Methods Co-citation cluster analysis of high-frequency citations, combined with co-word cluster analysis of high-frequency of MeSH terms were used to discover research focuses. This was followed by statistical analysis of the content of each cluster, and demonstration of the research trends through citation and subject strategic diagrams. Results Eight hot sub-fields have been identified both before and after 2002, which include both cross and separate topics. Conclusion With a multi-disciplinary characteristic, health management has not yet developed into a mature and stable research field; Health management involves the whole management process of healthcare services; Mental health management, chronic disease management and its primary health care service are all constant hotspots of studies. Health literacy is an area deserving greater attention in health management; Health management should interact with health insurance,making it part of the medical insurance system.     

非小细胞肺癌胰岛素样生长因子-1受体的表达与预后关系

胰岛素样生长因子1受体(insulin like growth factor-1 receptor,IGF-1R)是一种跨膜的酪氨酸蛋白受体,对细胞的分裂分化和增殖具有重要的调控作用[1]。为进一步探讨IGF-1R临床的预后价值,本研究以细针穿刺或纤维支气管镜病理活检确诊为NSCLC为研究对     

耐多药结核病诊疗管理试点地区耐药基线调查结果分析

摘要：目的 根据中国全球基金耐多药结核病（multidrug-resistant tuberculosis, MDR-TB）项目（简称“项目”）试点地区深圳、武汉市耐药基线调查结果,检验深圳、武汉市使用的耐多药结核病标准化治疗方案的合理性。方法 对2008年1月1日至12月31日期间,深圳（41株）和武汉市（64株）耐药基线调查分离出的105株耐HR（异烟肼,利福平）菌株进行链霉素（stréptomycin, S）、乙胺丁醇（ethambutol, E）、卡那霉素（kanamycin,Km）和氧氟沙星（ofloxacin, Ofx）4种药物的药敏试验,其中58株来自初治患者,47株来自复治患者。利用获得的耐药谱分析标准化治疗方案制定的合理性。将检测结果录入Epidata数据库,利用SAS软件进行分析。对耐药情况采用率和构成比描述。计数资料的组间比较采用χ²检验、Fisher确切概率法检验。P值＜0.05为差异有统计学意义。结果 105株MDR-TB菌株中,对S、E、Km和Ofx的耐药率分别为74.3%、41.0%、11.4%、22.9%,其中初治组对S、E、Km和Ofx的耐药率分别为75.9%、41.4%、10.3%和19.0%;复治组对S、E、Km和Ofx的耐药率分别为72.3%、40.4%、12.8%和27.7%,比较初、复治MDR-TB患者对S、E、Km和Ofx的耐药率,差异无统计学意义（χ²值分别为0.001、0.013、0.231和1.423,P值均＞0.05）。深圳市初治组对S、E、Km和Ofx的耐药率分别为76.0%、40.0%、16.0%和4.0%;复治组对S、E、Km和Ofx的耐药率分别为68.8%、43.8%、6.3%和18.8%,武汉市初治组对S、E、Km和Ofx的耐药率分别为75.8%、42.4%、6.1%和30.3%;复治组对S、E、Km和Ofx的耐药率分别为74.2%、38.7%、16.1%和32.3%。比较深圳和武汉市MDR-TB患者耐药情况,武汉市初治患者对Ofx的耐药率高于深圳市（χ²=6.4033,P<0.05）,其他3种药的耐药率差异无统计学意义;两市复治患者的4种药耐药率差异均无统计学意义（P值均＞0.05）。结论 目前采用的标准化治疗方案基本符合深圳市耐药谱,适用于深圳市的初、复治MDR-TB患者治疗;该方案用于武汉市MDR-TB患者治疗时,能否将Ofx作为标准方案的主要药物之一有待进一步研究。     

中药血清体外药效研究存在的问题与对策

中药血清体外药效研究是近年来中药研究新的发展趋向,它模拟中药在体的吸收、转化、代谢的过程,通过采集动物含药血清,进行相关的体外药效学研究.     

Effect of Feitai Capsule(肺泰胶囊) on Quality of Life and Progression-Free Survival of Patients with Unresectable Non-Small Cell Lung Cancer

<正>Objective:To examine the effect of a Chinese medicinal herbal formula(Feitai Capsule,肺泰胶囊) on the quality of life(QOL) and progression-free survival(PFS) of patients with unresectable non-small cell lung cancer(NSCLC).Methods:Sixty-two patients were randomly divided into the treatment group(31 cases) and the control group(31 cases).For the treatment group,4 capsules(1.2 g/capsule) of Feitai Capsule were administered 3 times a day after meals for 3 weeks;then no drug was administered for 1 week.This schedule was continued for at least 3 more cycles(12 weeks totally).If there were no obvious toxic reactions,the treatment was extended.The patients were evaluated at least once every 8 weeks until progressive disease(PD). For the control group,the regular follow-up and evaluation were performed at least once every 8 weeks until PD.Clinical symptoms,objective response,physical constitution and energy,QOL,and PFS were evaluated regularly.Analysis of variance(ANOVA),a non-parametric test,and analysis of covariance were used to compare clinical features,amelioration of clinical symptoms,physical constitution and energy,and QOL.Kaplan-Meier analysis was used to compare the two-group PFS.Results:Sixty patients finished the final evaluation, with 30 patients in each group.Baseline characters between groups were not significantly different(P0.05). The control group had a 36.7%improvement in clinical symptoms,while the treatment group had a 73.3% improvement.This difference was statistically significant(Z=-2.632,P=0.008).The control group had a 26.7% improvement in the Karnofsky performance status(KPS),while the treatment group had a 53.4%improvement. This was also significantly different(Z=-2.182,P=0.029).A comparative analysis indicated a positive correlation (r=0.917,P0.001).Compared with the control group,QOL in the treatment group was significantly improved, except in the social/family condition and doctor-patient relationship indicators.The PFS of the treatment group and control group were 6.23 months and 4.67 months,respectively(P=0.048).Conclusion:Feitai Capsule,a Chinese medicinal herbal treatment could improve the QOL and extend the PFS of the unresectable NSCLC patients.     

国际植物药研究科技论文的计量分析

以PubMed数据库为数据源,利用普赖斯指数增长定律、布拉德福定律等经典文献计量学方法和关联规则等文本挖掘技术,对目前国际植物药研究文献的增长规律、高产国家和机构、核心期刊,以及研究的热点、前沿领域进行了系统、全面的分析,以把握国际植物药研究的态势和对我国中药事业发展的影响,并提出了相应的对策.